CJC-1295
Growth hormone–releasing hormone (GHRH) analog
Quick Answer
A synthetic peptide designed to mimic and extend the activity of growth hormone–releasing hormone, which stimulates the pituitary gland to release growth hormone. Exists in variants with and without a "drug affinity complex" (DAC) that extends its half-life — these variants should be distinguished when discussed, not treated as one compound.
Why People Are Interested
Popular in the growth-hormone-optimization conversation as a longer-acting alternative to older GHRH-pathway compounds, often discussed alongside ipamorelin as a "stack."
What People Hope It May Do
Increased growth hormone release for body-composition and recovery goals — a plausible mechanism, but one studied mostly in small or early-stage settings rather than large controlled trials. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Growth hormone secretion dynamics
Potential body-composition-related research questions (mostly community-driven interest rather than a deep clinical trial base)
How It May Work
Binds GHRH receptors in the pituitary to stimulate growth hormone release, similar to natural GHRH but with a longer duration of action than the native hormone.
What Human Research Shows
Limited public clinical trial data; most available human information comes from earlier-stage or smaller studies rather than large controlled trials of the kind supporting an FDA-approved product.
What Preclinical Research Shows
Growth-hormone-axis pharmacology research, with more extensive preclinical characterization than human data.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to CJC-1295 is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving CJC-1295, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
No comprehensive, controlled human safety database exists publicly at the scale of an approved drug. Effects related to growth hormone elevation generally are an active research and clinical-monitoring topic that requires licensed medical oversight, not consumer self-guidance.
Regulatory Status
Not FDA-approved. Not available as an approved prescription product for any indication; commonly found in the gray-market "research chemical" space, which this business does not sell into.
What We Still Don't Know
Long-term safety of sustained growth-hormone-axis stimulation outside a supervised clinical context, and whether real-world body-composition outcomes match the mechanism's promise.
Limitations of Evidence
Sparse controlled human data; variant (with/without DAC) is often not clearly distinguished in available sources, which is itself a data-quality problem worth flagging in any article.
Keep Researching
- Search ClinicalTrials.gov for CJC-1295
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-08-15